

[IBC | Institutional Biosafety Committee](#)

The Institutional Biosafety Committee (IBC) advises the Chancellor through the Vice Chancellor – Resource Management & Planning on all matters relating to the safe use of hazardous biological materials and organisms.

The IBC establishes, monitors and enforces policies and procedures which meet or exceed applicable norms or regulations for biohazardous materials and/or recombinant DNA, including gene transfer clinical trials. Any use of biohazardous materials and/or recombinant DNA must be reviewed and approved by the IBC (or the Biological Safety Officer operating within guidelines established by the IBC).

The IBC has the authority to impose disciplinary measures in cases where there is willful or negligent violation of UC San Diego's established biosafety practices and procedures. Sanctions are subject to review and/or modification by the Chancellor. The IBC shall maintain diverse membership representing the community and a variety of university interests. Non-committee faculty or staff with a particular expertise will be asked to advise the committee when the need arises.

Principal investigators, follow these [instructions for gene transfer clinical trial submission to UC San Diego's Institutional Biosafety Committee](#).

National Institutes of Health (NIH) [Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules](#) is the definitive reference for rDNA research in the United States and has been adopted by UC San Diego.

It is the principal investigator's responsibility to ensure ALL regulations and requirements are met.

[Contact EH&S Biosafety](#) with any questions.

Last updated: 26 Mar 2019

Source URL: <https://compass.ucsd.edu/ibc-institutional-biosafety-committee>



Drupal.jQueryUiFilter.globalOptions('accordion');